Free Trial
NYSEAMERICAN:TOVX

Theriva Biologics (TOVX) Stock Price, News & Analysis

Theriva Biologics logo
$1.18 0.00 (0.00%)
Closing price 04:10 PM Eastern
Extended Trading
$1.16 -0.02 (-1.69%)
As of 04:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Theriva Biologics Stock (NYSEAMERICAN:TOVX)

Key Stats

Today's Range
$1.07
$1.18
50-Day Range
$1.10
$1.72
52-Week Range
$1.03
$12.28
Volume
10,875 shs
Average Volume
994,946 shs
Market Capitalization
$3.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
Consensus Rating
Buy

Company Overview

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.

Remove Ads

Theriva Biologics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
52nd Percentile Overall Score

TOVX MarketRank™: 

Theriva Biologics scored higher than 52% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Theriva Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Theriva Biologics has received no research coverage in the past 90 days.

  • Read more about Theriva Biologics' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Theriva Biologics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Theriva Biologics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Theriva Biologics has a P/B Ratio of 0.02. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.55% of the float of Theriva Biologics has been sold short.
  • Short Interest Ratio / Days to Cover

    Theriva Biologics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Theriva Biologics has recently decreased by 16.92%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Theriva Biologics does not currently pay a dividend.

  • Dividend Growth

    Theriva Biologics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.55% of the float of Theriva Biologics has been sold short.
  • Short Interest Ratio / Days to Cover

    Theriva Biologics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Theriva Biologics has recently decreased by 16.92%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Theriva Biologics has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Theriva Biologics this week, compared to 1 article on an average week.
  • MarketBeat Follows

    3 people have added Theriva Biologics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Theriva Biologics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.05% of the stock of Theriva Biologics is held by insiders.

  • Percentage Held by Institutions

    Only 6.17% of the stock of Theriva Biologics is held by institutions.

  • Read more about Theriva Biologics' insider trading history.
Receive TOVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theriva Biologics and its competitors with MarketBeat's FREE daily newsletter.

TOVX Stock News Headlines

Theriva Biologics says IDMC considers VCN-01 to be well tolerated
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Headlines

TOVX Stock Analysis - Frequently Asked Questions

Theriva Biologics' stock was trading at $1.65 at the start of the year. Since then, TOVX shares have decreased by 28.5% and is now trading at $1.18.
View the best growth stocks for 2025 here
.

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) issued its quarterly earnings results on Tuesday, November, 12th. The company reported ($6.81) EPS for the quarter, missing analysts' consensus estimates of ($6.25) by $0.56.

Shares of Theriva Biologics reverse split on Monday, August 26th 2024. The 1-25 reverse split was announced on Friday, August 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Shares of TOVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Theriva Biologics investors own include BIOLASE (BIOL), Jiuzi (JZXN), Daré Bioscience (DARE), Dermata Therapeutics (DRMA), Faraday Future Intelligent Electric (FFIE), Adial Pharmaceuticals (ADIL) and Aditxt (ADTX).

Company Calendar

Last Earnings
11/12/2024
Today
4/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSEAMERICAN:TOVX
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$6.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+417.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-18,350,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$54.22 per share
Price / Book
0.02

Miscellaneous

Free Float
2,697,000
Market Cap
$3.22 million
Optionable
Not Optionable
Beta
1.22
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NYSEAMERICAN:TOVX) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners